EcoDrugPlus

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSORLG00000018295
Gene Symbol: PSMB10
4 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSORLG00000009748
Gene Symbol: PSMB2
4 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSORLG00000019520
Gene Symbol: PSMB3
4 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSORLG00000001283
Gene Symbol: PSMB4
4 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSORLG00000026171
Gene Symbol: PSMB5
4 Cross references
203 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSORLG00000013170
Gene Symbol: PSMB7
4 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSORLG00000006783
Gene Symbol: PSMB8A
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSORLG00000006646
Gene Symbol: PSMB9A
3 Cross references
203 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSORLG00000009401
Gene Symbol: PSMD2
4 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSORLG00000015825
Gene Symbol: PSMC1
4 Cross references
281 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSORLG00000018441
Gene Symbol: PSMC2
4 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSORLG00000010768
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).